Paul G Savas Net Worth

The estimated Net Worth of Paul G Savas is at least $2.31 Millón dollars as of 21 May 2020. Paul Savas owns over 15,000 units of SIGA Technologies Inc stock worth over $2,311,931 and over the last 20 years Paul sold SIGA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Paul Savas SIGA stock SEC Form 4 insiders trading

Paul has made over 30 trades of the SIGA Technologies Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently Paul exercised 15,000 units of SIGA stock worth $112,650 on 21 May 2020.

The largest trade Paul's ever made was exercising 66,664 units of SIGA Technologies Inc stock on 16 November 2016 worth over $6,666,166,676. On average, Paul trades about 8,778 units every 85 days since 2004. As of 21 May 2020 Paul still owns at least 307,847 units of SIGA Technologies Inc stock.

You can see the complete history of Paul Savas stock trades at the bottom of the page.

What's Paul Savas's mailing address?

Paul's mailing address filed with the SEC is C/O SIGA TECHNOLOGIES, INC.,, 31 EAST 62ND STREET, NEW YORK, NY, 10065.

Insiders trading at SIGA Technologies Inc

Over the last 21 years, insiders at SIGA Technologies Inc have traded over $65,185,125 worth of SIGA Technologies Inc stock and bought 6,065,626 units worth $33,817,674 . The most active insiders traders include Holdings Incperelman Ronald..., Pharma Inc Transtech y Adnan M M Mjalli. On average, SIGA Technologies Inc executives and independent directors trade stock every 36 days with the average trade being worth of $1,122,865. The most recent stock trade was executed by Dennis E Hruby on 1 July 2024, trading 32,258 units of SIGA stock currently worth $242,258.

What does SIGA Technologies Inc do?

at siga, we specialize in developing therapeutic solutions for some of the most lethal pathogens – smallpox, ebola, dengue, lassa fever and other dangerous viruses. our objective is to discover, develop, and commercialize drugs to prevent and treat these high-priority threats.

Complete history of Paul Savas stock trades at vTv Therapeutics Inc, Revlon y SIGA Technologies Inc

SIGA Technologies Inc executives and stock owners

SIGA Technologies Inc executives and other stock owners filed with the SEC include:

• Daniel Luckshire,
  Chief Financial Officer, Executive Vice President, Secretary
• Dr. Phillip Louis Gomez III, M.D., Ph.D.,
  CEO & Director
• Phillip Gomez,
  Chief Executive Officer, Director
• Robin Abrams,
  Chief Administrative Officer, General Counsel
• Dr. Dennis E. Hruby,
  Exec. VP & Chief Scientific Officer
• Dennis Hruby,
  Chief Scientific Officer, Vice President
• Daniel J. Luckshire,
  Exec. VP, CFO & Sec.
• Robin E. Abrams,
  Gen. Counsel & Chief Admin. Officer
• Eric Rose,
  Chairman of the Board
• Julie Kane,
  Independent Director
• Michael Plansky,
  Independent Director
• Joseph Marshall,
  Independent Director
• James Antal,
  Independent Director
• Thomas Constance,
  Independent Director
• Herb Vloedman,
  Chief Information Officer
• Tove C. Bolken,
  Sr. VP of Operations & Chief Supply Chain Officer
• Diem Nguyen,
  Chief Executive Officer
• Larry R. Miller,
  General Counsel
• Holdings Incperelman Ronald...,
  
• Bruce Slovin,
  Director
• Paul G Savas,
  
• Jeffrey B Kindler,
  
• Scott M Hammer,
  Director
• Donald G Drapkin,
  Director
• Bernard L Kasten,
  Chief Executive Officer
• Ayelet Dugary,
  Acting Chief Financial Officer
• Judy S Slotkin,
  Director
• Michael Md Weiner,
  Director
• Thomas N Konatich,
  CFO, Secretary and Treasurer
• Adnan M M Mjalli,
  Director
• John Odden,
  VP - Business Development
• Ronald O Mac Andrews & Forb...,
  
• William C Bevins,
  Director
• Susan K Burgess,
  President
• Michael J Bayer,
  Director
• Frances F Townsend,
  Director
• William J Ii Haynes,
  Executive VP & General Counsel
• Steven L Fasman,
  Director
• Pharma Inc Transtech,
  10% owner
• & Forbes Holdings Inc.Perel...,
  
• Mehmet C Md Oz,
  Director
• Donald G Drapkin,
  Director
• Evan A. Knisely,
  
• Edward P. Taibi,
  
• Holly L. Phillips,
  
• Jaymie A Durnan,
  
• Gary J. Nabel,
  
• Julian Nemirovsky,
  
• Harold Eugene Jr. Ford,
  
• Jay Varma,
  EVP & Chief Medical Officer